{"product_id":"edgewisetx-business-model-canvas","title":"Edgewise Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompact Business Model Canvas for RNA-Targeted Therapeutics: Value, Partners, Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore a concise Business Model Canvas for Edgewise Therapeutics that maps its value proposition, key partnerships, channels, and revenue levers to reveal how it advances RNA-targeted therapies to market. This snapshot highlights strategic risks and growth paths. Purchase the full, editable Canvas for a complete, investor-ready blueprint. Download in Word and Excel to apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic neuromuscular centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with leading university and hospital neuromuscular centers specializing in DMD\/BMD to access concentrated patient cohorts (DMD prevalence ~1 in 3,500–5,000 male births; US estimated 15,000–19,000 affected) and deep clinical expertise. These centers enable efficient trial enrollment and high-quality phenotyping. Collaboration accelerates protocol design and biomarker validation. Co-authorship and shared datasets enhance credibility and external visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngage DMD\/BMD foundations (DMD incidence ~1 in 3,500–5,000 male births) to align Edgewise development with patient needs; foundations boost trial awareness and can shorten enrollment timelines. They provide real-world insights, help facilitate grant and philanthropic funding, and support regulatory interactions, building trust through ongoing dialogue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract research and manufacturing organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise leverages specialized CROs and CDMOs for preclinical studies, clinical operations, and GMP manufacturing to scale programs rapidly while avoiding heavy fixed capital expenditure. These partnerships enable cost control and flexible capacity, with established quality systems that lower operational and compliance risk. Global vendor networks support multi-region trials and streamline pathways to commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and health economics advisors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise leverages regulatory and health-economics advisors for FDA\/EMA strategy, orphan designation pursuit and payer evidence generation; early input shapes endpoints, sample sizes and accelerated pathways, reducing regulatory risk. FDA Priority Review target is 6 months and EMA accelerated assessment is 150 days (2024). HEOR guidance aligns value dossiers with HTA requirements and pricing negotiations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory strategy: FDA\/EMA timelines (6 months; 150 days)\u003c\/li\u003e\n\u003cli\u003eOrphan\/payer: targeted designation \u0026amp; evidence plans\u003c\/li\u003e\n\u003cli\u003eHEOR: HTA-ready value dossiers to de-risk pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic pharma collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic pharma collaborators structure co-development, licensing, or commercialization alliances in select geographies to leverage partners’ scale in medical affairs, market access, and distribution; the global orphan drug market was valued at about 216 billion USD in 2024, underscoring addressable opportunity. Milestone-based funding extends runway and shares risk, while joint governance accelerates launch readiness in rare disease markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development\/licensing: regional focus\u003c\/li\u003e\n\u003cli\u003ePartner strengths: medical affairs, market access, distribution\u003c\/li\u003e\n\u003cli\u003eFunding: milestone-driven to de-risk\u003c\/li\u003e\n\u003cli\u003eGovernance: joint launch readiness for rare diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerate DMD trials: partner centers, foundations, CROs and pharma to de-risk programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartner with neuromuscular centers for access to concentrated DMD cohorts (prevalence ~1\/3,500–5,000 male births; US ~15–19k patients) to speed enrollment and biomarker validation.\u003c\/p\u003e\n\u003cp\u003eEngage DMD foundations for recruitment, funding and regulatory support; CROs\/CDMOs provide scalable GMP and global trial capacity.\u003c\/p\u003e\n\u003cp\u003ePharma co-development and HEOR\/regulatory advisors de-risk pathways (orphan market ~$216B in 2024; FDA priority 6m; EMA 150d in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eCenters\u003c\/td\u003e\n\u003ctd\u003eEnrollment\/phenotyping\u003c\/td\u003e\n\u003ctd\u003e15–19k US pts\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BMC for Edgewise Therapeutics: a clinical-stage biotech developing precision small-molecule therapies for neurological and neuromuscular disorders, monetizing via partnerships, licensing, and eventual product launches; covers customer segments (patients, payers, partners), value propositions (novel mechanisms, clinical progress), channels, revenue streams, cost structure, key activities\/resources\/partners, and linked SWOT and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Edgewise Therapeutics’ business model that pinpoints how their therapies relieve patient and payer pain points in one editable canvas for fast team alignment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development for DMD\/BMD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and execute Phase 1–3 trials for orally bioavailable small molecules in DMD\/BMD, targeting cohorts of ~50–300 patients across phases to assess dose and safety.\u003c\/p\u003e\n\u003cp\u003eOptimize dose, safety, and functional efficacy using 6MWT, NSAA and quantitative dystrophin biomarker assays.\u003c\/p\u003e\n\u003cp\u003eIncorporate patient-reported outcomes and pulmonary function measures and align registrational endpoints with FDA and EMA requirements across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy and engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecure US orphan and rare pediatric designations to access 7 years US and 10 years EU exclusivity, pursue expedited pathways (Fast Track\/Breakthrough\/Priority Review, PRIME) to target a 6‑month FDA review or 210 active day EMA centralized MAA; hold quarterly FDA\/EMA alignments on endpoints and CMC, maintain compliant documentation and SAE reporting (7‑day IND safety report window), and map NDA\/MAA dossiers and advisory committee timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC scale-up and quality management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDevelop and scale API and drug product processes to multi-kilogram manufacturing suitable for chronic dosing, with process validation per ICH Q8 principles. Validate analytical methods under ICH Q2(R1) and run stability programs per ICH Q1A(R2) long-term protocols (minimum 12 months) plus accelerated studies. Build supply chain redundancy with ≥2 qualified suppliers for critical materials to target \u0026gt;99% continuity. Implement a QMS aligned to ICH and GMP requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTranslational and biomarker research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTranslational and biomarker research targets pharmacodynamic markers of muscle protection in DMD\/BMD including serum CK (often 10–100x normal), MRI muscle fat fraction (detectable 5–15% annual change), and functional endpoints like 6MWT (MCID ~30 m). Preclinical mdx and GRMD models are used to link mechanisms to clinical outcomes and de-risk programs. Imaging, serum biomarkers and timed functional tests demonstrate mechanism and are iterated with interim data to refine trial designs and endpoints.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003emdx and GRMD models: bridge preclinical to clinical\u003c\/li\u003e\n\u003cli\u003eCK elevation: 10–100x normal\u003c\/li\u003e\n\u003cli\u003eMRI fat fraction change: ~5–15%\/yr\u003c\/li\u003e\n\u003cli\u003e6MWT MCID: ~30 meters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and launch preparation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenerate payer-ready evidence in 2024 including burden-of-illness and economic models to support value-based contracting and formulary access. Map KOLs and centers of excellence to prioritize high-volume sites and accelerate trial-to-launch transitions. Educate clinicians and patient groups on clinical differentiation while building specialty pharmacy and distribution strategies to ensure timely access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEvidence: burden, economic models (2024 focus)\u003c\/li\u003e\n\u003cli\u003eKOL\/COE mapping\u003c\/li\u003e\n\u003cli\u003eClinician \u0026amp; patient education\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy \u0026amp; distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDesign Phase 1–3 DMD\/BMD \u003cstrong\u003e50–300\u003c\/strong\u003e pts; refine dose, 6MWT, dystrophin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/execute Phase 1–3 DMD\/BMD trials (50–300 pts\/ph); refine dose\/safety using 6MWT, NSAA, dystrophin assays and PROs.\u003c\/p\u003e\n\u003cp\u003eSecure US orphan\/rare pediatric exclusivity; pursue Fast Track\/Breakthrough\/PRIME; maintain QMS, GMP, ICH validation and ≥2 suppliers.\u003c\/p\u003e\n\u003cp\u003eTranslate biomarkers (CK 10–100x; MRI fat change 5–15%\/yr; 6MWT MCID ~30 m); generate 2024 payer economic models.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase size\u003c\/td\u003e\n\u003ctd\u003e50–300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCK\u003c\/td\u003e\n\u003ctd\u003e10–100x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRI fat\u003c\/td\u003e\n\u003ctd\u003e5–15%\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6MWT MCID\u003c\/td\u003e\n\u003ctd\u003e~30 m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Edgewise Therapeutics Business Model Canvas shown here is the actual document, not a mockup, and reflects the full structure and content you’ll receive after purchase. When you complete your order you’ll get this same professional, ready-to-edit file, formatted for immediate use. No placeholders, no surprises—what you see is what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161422967161,"sku":"edgewisetx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/edgewisetx-business-model-canvas.png?v=1762692656","url":"https:\/\/portersfiveforce.com\/products\/edgewisetx-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}